KalVista Pharmaceuticals, Inc.

As of October 10, 2025, KalVista Pharmaceuticals, Inc. exhibits a neutral technical trend with mixed signals, showing mildly bearish MACD and Bollinger Bands on both weekly and monthly charts, while daily moving averages remain mildly bullish, indicating a lack of strong momentum.

As of October 10, 2025, KalVista Pharmaceuticals has shifted to a neutral trend with mixed signals, underperforming the S&P 500 in the past month but significantly outperforming it over the last three years.

As of October 10, 2025, KalVista Pharmaceuticals' technical trend is neutral with mixed indicators, showing a recent shift from mildly bullish to sideways, and while it has underperformed the S&P 500 over the past month and year, it has significantly outperformed it over the last three years.

As of September 12, 2025, KalVista Pharmaceuticals, Inc. shows a mildly bullish trend with positive momentum from MACD and moving averages, but mixed indicators suggest caution despite strong year-to-date and annual returns compared to the S&P 500.

As of September 11, 2025, KalVista Pharmaceuticals, Inc. is considered risky and overvalued due to significant negative financial metrics, including a Price to Book Value of 4.92 and an ROE of -121.18%, while its performance has underperformed the S&P 500 despite a YTD return of 63.87%.

KalVista Pharmaceuticals, Inc. is currently considered overvalued and has been downgraded to a "does not qualify" valuation grade due to significant financial distress, reflected in its poor performance indicators and underperformance compared to the S&P 500.

As of June 17, 2025, the trend is mildly bullish due to daily moving averages and monthly OBV, despite some caution from weekly MACD and KST, with RSI showing no momentum signals.

As of March 2022, the management team of KalVista Pharmaceuticals, Inc. includes Dr. Martin Edwards (Independent Chairman), Mr. Thomas Crockett (CEO), and several independent directors: Dr. Albert Cha, Mr. Arnold Oronsky, Dr. Brian Pereira, Mr. Daniel Soland, and Mr. Edward Unkart. They oversee the company's strategic direction and operations.

KalVista Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in small molecule protease inhibitors. It has a market cap of $603.80 million and reported a net profit loss of $49 million as of January 2025.

As of Jun 18, KalVista Pharmaceuticals, Inc. has a market capitalization of 603.80 million, classifying it as a Micro Cap company, with net sales of 0.00 million and a net profit of -175.87 million over the latest four quarters. As of Apr 24, the company reported shareholder's funds of 206.58 million and total assets of 235.40 million.